Cell and gene therapies (CGT) are proving their worth as life-saving treatments, from cancers to rare diseases, but bringing these innovations to the masses will require substantial advances in manufacturing, and not everyone agrees on what those advances look like. Which approaches prove best will depend on many factors, from the therapies themselves to the legal and payer issues that surround this space. Moreover, current and future innovations in manufacturing are not mutually exclusive, and developers don’t have to work in silos. Combining manufacturing techniques and cooperation across the space is necessary to maximize the reach of these life-saving therapies. In this panel, tools and services representatives discuss their different approaches to scaling CGT manufacturing, with additional experts weighing in on challenges and how they might fit together.